Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

被引：0
|
作者：
N. L. Steele
J. A. Plumb
L. Vidal
J. Tjørnelund
P. Knoblauch
P. Buhl-Jensen
R. Molife
R. Brown
J. S. de Bono
T. R. J. Evans
机构：
[1] Beatson West of Scotland Cancer Centre,Centre for Oncology and Applied Pharmacology
[2] University of Glasgow,undefined
[3] Royal Marsden Hospital,undefined
[4] Topotarget,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Histone deacetylase; Phase-1 trial; Pharmacokinetics; Pharmacodynamics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1273 / 1279
页数：6
相关论文
共 50 条
  • [21] A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
    Hansen, M
    Gimsing, P
    Rasmussen, A
    Jensen, PB
    Knudsen, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 225S - 225S
  • [22] Effect of the histone deacetylase (HDAC) inhibitor PXD101 on the human colon carcinoma cell line FET
    McArdle, Jessica K.
    Brattain, Michael
    Howell, Gillian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 757 - 757
  • [23] The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models
    Young-Soon Na
    Kyung-Ah Jung
    Seung-Mi Kim
    Yong Sang Hong
    Min-Hee Ryu
    Se Jin Jang
    Dae Hyuk Moon
    Dong-Hyung Cho
    Jin Cheon Kim
    Jung Shin Lee
    Tae Won Kim
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 389 - 398
  • [24] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
    Kelly, W. K.
    Yap, T.
    Lee, J.
    Lassen, U.
    Crowley, E.
    Clarke, A.
    Hawthorne, T.
    Buhl-Jensen, P.
    de Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY
    Kaimakliotis, Hristos Z.
    Martin, Darryl T.
    Hoimes, Christopher J.
    Cheng, Christopher C.
    Liu, Jingchun
    Kelly, Wm. Kevin
    Tew, Gregory N.
    Saltzman, W. Mark
    Weiss, Robert M.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E542 - E542
  • [26] Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma
    Zain, J. M.
    Foss, F.
    Kelly, W. K.
    DeBono, J.
    Petrylak, D.
    Narwal, A.
    Neylon, E.
    Blumenschein, G.
    Lassen, U.
    O'Connor, O. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
    Molife, Rhoda
    Lee, James
    Petrylak, Daniel
    Blumenschein, George, Jr.
    Lassen, Ulrik
    Clark, Jayme
    Yap, Timothy
    Rowen, Elin
    Ang, Jooern
    Crowley, Elizabeth
    Clarke, Anne
    Hawthorne, Thomas
    Buhl-Jensen, Peter
    De Bono, Johann
    Kelly, Wm Kevin
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3476S - 3476S
  • [28] The histone deacetylase inhibitor PXD101 inhibits the growth of human ovarian and colon tumour xenografts in vivo.
    Plumb, JA
    Williams, RJ
    Finn, PW
    Bandara, MJ
    Romero, MR
    Watkins, CJ
    La Thangue, NB
    Brown, R
    BRITISH JOURNAL OF CANCER, 2002, 86 : S16 - S16
  • [29] Updated results of the first in man evaluation of the histone deacetylase (HDAC) inhibitor, PXD101 in cancer patients (pts).
    de Bono, JS
    Steele, N
    Vidal, L
    Reid, A
    Marriott, C
    Tjornelund, J
    Shaw, H
    Plumb, J
    Molife, R
    Morrison, R
    Fong, P
    Buhl-Jensen, P
    Rasmussen, A
    Evans, TRJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9121S
  • [30] Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors
    Kelly, W. K.
    DeBono, J.
    Blumenschein, G.
    Lassen, U.
    Zain, J.
    O'Connor, O.
    Foss, F.
    Tjornelund, J.
    Fagerberg, J.
    Petrylak, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345